These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38738254)

  • 21. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term trajectories of SARS-CoV-2 neutralizing antibodies and predictive value of first dose vaccination-induced IgG-antibodies in hemodialysis patients.
    Tillmann FP; Still H; von Landenberg P
    Int Urol Nephrol; 2022 Aug; 54(8):1939-1945. PubMed ID: 34860338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis of clinical characteristics of patients with different vaccines and underlying diseases infected with novel coronavirus Omicron variant].
    Xu H; Wang J; Gao H; Wang Y
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Jun; 34(6):571-575. PubMed ID: 35924509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiological and clinical characteristics of COVID-19 reinfection during the epidemic period in Yangzhou city, Jiangsu province.
    Wang Y; Liang J; Yang H; Zhu L; Hu J; Xiao L; Huang Y; Dong Y; Wu C; Zhang J; Zhou X
    Front Public Health; 2023; 11():1256768. PubMed ID: 37780420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19.
    Kim YJ; Bae JY; Bae S; Hwang S; Kwon KT; Chang HH; Lee WK; Cui C; Lee GE; Kim SW; Park MS
    Yonsei Med J; 2021 Jul; 62(7):584-592. PubMed ID: 34164955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reinfection rates, change in antibody titers and adverse events after COVID-19 vaccination among patients previously infected with COVID-19 in Metro Manila, Philippines: a secondary analysis of a completed cohort study.
    Tan-Lim CSC; Gonzales MLAM; Dans LF; Cordero CP; Alejandria MM; Dela Paz ECC; Dator MA; Infantado-Alejandro MAJ; Sulit MVV; Lansang MAD
    BMC Infect Dis; 2023 Nov; 23(1):750. PubMed ID: 37915006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals.
    Dai YC; Lin YC; Ching LL; Tsai JJ; Ishikawa K; Tsai WY; Chen JJ; Nerurkar VR; Wang WK
    Microbiol Spectr; 2023 Aug; 11(4):e0408122. PubMed ID: 37428104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Limited Effect of a History of COVID-19 on Antibody Titers and Adverse Reactions Following BNT162b2 Vaccination: A Single-Center Prospective Study.
    Kushima H; Ishii H; Kinoshita Y; Koide Y; Komiya Y; Kato J; Umehara M; Sakata M; Miyazaki M; Ikuta M
    J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36143040
    [No Abstract]   [Full Text] [Related]  

  • 30. Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination.
    Takahashi T; Ai T; Saito K; Nojiri S; Takahashi M; Igawa G; Yamamoto T; Khasawneh A; Paran FJ; Takei S; Horiuchi Y; Kanno T; Tobiume M; Hiki M; Wakita M; Miida T; Okuzawa A; Suzuki T; Takahashi K; Naito T; Tabe Y
    PLoS One; 2023; 18(9):e0291670. PubMed ID: 37725623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterizing Longitudinal Antibody Responses in Recovered Individuals Following COVID-19 Infection and Single-Dose Vaccination: A Prospective Cohort Study.
    Olmstead AD; Nikiforuk AM; Schwartz S; Márquez AC; Valadbeigy T; Flores E; Saran M; Goldfarb DM; Hayden A; Masud S; Russell SL; Prystajecky N; Jassem AN; Morshed M; Sekirov I
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
    Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
    PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Observational study of antibody levels after second and third SARS-CoV-2 vaccinations in medical workers.
    Liu Q; Zhou W; Jiang W; Jia X
    J Clin Lab Anal; 2022 Nov; 36(11):e24731. PubMed ID: 36250228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants.
    Cardemil CV; Cao Y; Posavad CM; Badell ML; Bunge K; Mulligan MJ; Parameswaran L; Olson-Chen C; Novak RM; Brady RC; DeFranco E; Gerber JS; Pasetti M; Shriver M; Coler R; Berube B; Suthar MS; Moreno A; Gao F; Richardson BA; Beigi R; Brown E; Neuzil KM; Munoz FM;
    Pediatrics; 2024 Mar; 153(3):. PubMed ID: 38332733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variation in antibody titers determined by Abbott and Roche Elecsys SARS-CoV-2 assays in vaccinated healthcare workers.
    Nakai M; Yokoyama D; Sato T; Sato R; Kojima C; Shimosawa T
    Heliyon; 2023 Jun; 9(6):e16547. PubMed ID: 37235203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained seropositivity up to 20.5 months after COVID-19.
    Dobaño C; Ramírez-Morros A; Alonso S; Rubio R; Ruiz-Olalla G; Vidal-Alaball J; Macià D; Catalina QM; Vidal M; Casanovas AF; Prados de la Torre E; Barrios D; Jiménez A; Zanoncello J; Melero NR; Carolis C; Izquierdo L; Aguilar R; Moncunill G; Ruiz-Comellas A
    BMC Med; 2022 Oct; 20(1):379. PubMed ID: 36224590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High and Persistent Anti-GM1 Antibody Titers Are Associated With Poor Clinical Recovery in Guillain-Barré Syndrome.
    Thomma RCM; Fokke C; Walgaard C; Vermeulen-de Jongh DMC; Tio-Gillen A; van Rijs W; van Doorn PA; Huizinga R; Jacobs BC
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37059469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-spike Antibody Status in Pre-vaccinated Healthy Participants and Rheumatoid Arthritis Patients During the Third Wave of COVID-19.
    Eerike M; Sundaramurthy R; Gandham R; Sakthivadivel V; Amshala A; Priyadarshini R; Pyati AK; Patil P
    Cureus; 2023 Apr; 15(4):e37316. PubMed ID: 37181975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.